openPR Logo
Press release

Non-Viral Drug Delivery Systems Market is expected to surpass USD 110.7 billion by 2034

09-15-2025 10:18 AM CET | Health & Medicine

Press release from: Exactitude Consultancy

Non-Viral Drug Delivery Systems

Non-Viral Drug Delivery Systems

Drug delivery is one of the most critical aspects of modern medicine, ensuring that therapeutics reach their intended site of action safely and effectively. While viral vectors have long been used for gene and drug delivery, their safety limitations, immunogenicity, and manufacturing challenges have accelerated interest in non-viral drug delivery systems.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73463

These systems include lipid nanoparticles (LNPs), polymer-based carriers, dendrimers, micelles, and inorganic nanoparticles. They are central to mRNA vaccines, gene therapies, oncology treatments, and chronic disease management. With the rise of personalized medicine, biologics, and RNA-based therapeutics, the demand for non-viral systems is growing rapidly.

Market Overview
• Market Size (2024): USD 52.3 billion
• Forecast (2034): USD 110.7 billion
• CAGR (2025-2034): 7.8%

Key Highlights:
• Non-viral delivery systems dominate RNA-based vaccine development.
• Growing adoption in oncology and rare-disease therapies.
• Safer alternatives to viral vectors, with scalable manufacturing.
• Heavy investment from pharma, biotech, and nanomedicine startups.

Segmentation Analysis
By Delivery System Type:
• Lipid-Based Systems (LNPs, liposomes)
• Polymer-Based Systems (PLGA, dendrimers, hydrogels)
• Inorganic Nanoparticles (gold nanoparticles, silica)
• Micelles & Emulsions
• Others (hybrid systems)

By Technology:
• Nanoparticle-Based Delivery
• Physical Methods (electroporation, ultrasound-mediated delivery)
• Chemical-Based Delivery (cationic polymers, pH-sensitive carriers)

By Application:
• Oncology (chemotherapy, immunotherapy delivery)
• Infectious Diseases (vaccines, antivirals)
• Genetic Disorders (gene silencing, mRNA therapies)
• Autoimmune & Chronic Diseases
• Others (neurology, ophthalmology)

By End Use:
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Specialty Clinics
• Contract Research & Manufacturing Organizations (CROs/CMOs)

Segmentation Summary:
Lipid nanoparticles (LNPs) lead the market, fueled by their success in COVID-19 mRNA vaccines and their use in ongoing RNA therapeutics. Polymer-based systems are expected to grow rapidly, offering versatility and biodegradability.

Explore Full Report here: https://exactitudeconsultancy.com/reports/73463/non-viral-drug-delivery-systems-market

Regional Analysis
North America
• Largest market (~45% share in 2024).
• Strong biotech ecosystem and mRNA therapeutic pipeline.
• FDA approvals of LNP-based vaccines boost adoption.
Europe
• ~30% share.
• EU investment in nanomedicine research.
• Germany, UK, and France leading in RNA vaccine and gene therapy research.
Asia-Pacific
• Fastest-growing region with CAGR of ~9.2%.
• Expanding biotech hubs in China, Japan, South Korea, and India.
• Increasing investments in local nanomedicine startups.
Middle East & Africa
• Emerging adoption for vaccine programs.
• Limited high-end research infrastructure but expanding collaborations.
Latin America
• Brazil and Mexico driving growth through vaccine adoption and clinical trials.
Regional Summary:
North America and Europe lead adoption today, while Asia-Pacific is the fastest-growing hub for nanomedicine and gene delivery, supported by expanding biotech ecosystems and government funding.
Market Dynamics
Key Growth Drivers:
• Expanding pipeline of RNA-based vaccines and therapies.
• Growing demand for oncology drug delivery systems.
• Advantages over viral vectors (lower immunogenicity, scalability).
• Expansion of nanomedicine R&D and manufacturing.

Key Challenges:
• Stability and delivery efficiency in complex biological environments.
• Manufacturing scale-up challenges.
• Regulatory uncertainties around newer nanocarriers.
• Cost and complexity of next-gen formulations.

Latest Trends:
• Growth of LNPs in RNA vaccine delivery beyond COVID-19.
• Development of hybrid carriers (lipid-polymer conjugates).
• Advances in stimuli-responsive carriers (pH, heat, light sensitive).
• Integration of AI in drug delivery system design.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73463

Competitor Analysis
Major Players in the Market:
• Moderna, Inc. (LNP-based mRNA vaccines and therapeutics)
• BioNTech SE
• Pfizer, Inc.
• Arbutus Biopharma Corp.
• CureVac N.V.
• Johnson & Johnson
• AstraZeneca plc
• Novartis AG
• Precision NanoSystems (PNI - lipid nanoparticle tech)
• Evonik Industries AG (nanoparticle manufacturing)

Competitive Summary:
Moderna, BioNTech, and Pfizer dominate RNA delivery via LNPs. Arbutus and CureVac drive innovation in lipid/polymer platforms. Precision NanoSystems and Evonik focus on enabling technologies. Competition is defined by delivery efficiency, stability, and therapeutic versatility.

Conclusion
The Non-Viral Drug Delivery Systems Market, valued at USD 52.3 billion in 2024, is projected to reach USD 110.7 billion by 2034, expanding at a CAGR of 7.8%.

Key Takeaways:
• Lipid nanoparticles dominate, polymer systems are fast-growing.
• Oncology and infectious disease applications lead adoption.
• North America and Europe dominate today, APAC grows fastest.
• Future growth will hinge on RNA-based therapies, hybrid systems, and scalable nanomedicine manufacturing.

Over the next decade, non-viral drug delivery will be central to precision medicine, RNA therapeutics, and next-gen biologics, creating major opportunities for pharma, biotech, and materials innovators.

This report is also available in the following languages : Japanese (非ウイルス性薬物送達システム市場), Korean (비바이러스 약물 전달 시스템 시장), Chinese (非病毒药物输送系统市场), French (Marché des systèmes d'administration de médicaments non viraux), German (Markt für nicht-virale Arzneimittelabgabesysteme), and Italian (Mercato dei sistemi di somministrazione di farmaci non virali), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/73463/non-viral-drug-delivery-systems-market#request-a-sample

Our More Reports:

Cell Therapy Media Market
https://exactitudeconsultancy.com/reports/73529/cell-therapy-media-market

Cell Therapy Packaging Market
https://exactitudeconsultancy.com/reports/73531/cell-therapy-packaging-market

Cold Chain Logistics Market
https://exactitudeconsultancy.com/reports/73533/cold-chain-logistics-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Viral Drug Delivery Systems Market is expected to surpass USD 110.7 billion by 2034 here

News-ID: 4182498 • Views:

More Releases from Exactitude Consultancy

Pulmonary Atresia Diagnostics & Treatment Market Expands as Advances in Pediatric Cardiology
Pulmonary Atresia Diagnostics & Treatment Market Expands as Advances in Pediatri …
Pune, India, November 14, 2025 - The Pulmonary Atresia Diagnostics & Treatment Market is experiencing steady global expansion as advancements in pediatric cardiology, neonatal critical care, imaging technologies, catheter-based interventions, and surgical reconstruction significantly improve patient outcomes. Exactitude Consultancy forecasts strong growth through 2034 driven by rising congenital heart disease (CHD) incidence, increased newborn screening, and growing availability of specialized pediatric cardiac centers. Download Full PDF Sample Copy of Market Report
Trauma Fixation Devices Market Accelerates as Road Injuries, Sports Accidents, and Orthopedic Surgical in 2025-2035
Trauma Fixation Devices Market Accelerates as Road Injuries, Sports Accidents, a …
Growing incidence of fractures, advancements in internal and external fixation systems, and expanding orthopedic infrastructure are driving strong global demand for trauma fixation devices. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/50182 Introduction The Trauma Fixation Devices Market is witnessing robust global growth as trauma cases-including fractures, dislocations, crush injuries, and complex orthopedic damage-continue to rise due to road accidents, falls, occupational injuries, sports activities, and aging populations. Trauma fixation devices
Medical Marijuana Market Surges as Legalization And Chronic Pain Management
Medical Marijuana Market Surges as Legalization And Chronic Pain Management
Pune, India, November 14, 2025 - The Medical Marijuana Market is expanding at an unprecedented pace as increasing global legalization, rising clinical acceptance, and growing demand for cannabis-based therapies drive industry transformation. Exactitude Consultancy forecasts strong growth through 2034, fueled by advancements in research, improved regulatory frameworks, and widespread adoption of medical marijuana for chronic pain, cancer care, neurological conditions, and mental health management. Download Full PDF Sample Copy of Market
Renal Cancer Drug Market Accelerates as Immunotherapy And Targeted Therapy
Renal Cancer Drug Market Accelerates as Immunotherapy And Targeted Therapy
Pune, India, November 14, 2025 - The Renal Cancer Drug Market is experiencing powerful global growth as rising incidence of kidney cancers-especially renal cell carcinoma (RCC)-drives demand for cutting-edge immunotherapies, targeted therapies, and precision oncology solutions. Exactitude Consultancy forecasts strong expansion through 2034, fueled by advancements in immune checkpoint inhibitors (ICIs), VEGF/VEGFR inhibitors, combination regimens, and personalized treatment protocols. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51880 Key Takeaways • Market projected

All 5 Releases


More Releases for RNA

CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes. CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034." According to the latest research by InsightAce Analytic,
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032. This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through - • 70% efforts of Primary Research • 15% efforts of Secondary Research • 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate? • The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%. • Expected exponential
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032. The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may